Hem/Onc Roundup: Disney Movies Improve Cancer Quality of Life; FDA Approvals for Gynecologic, Lung Cancers; and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a survey found that cancer research has been impacted by COVID-19, the U.S. Food and Drug Administration (FDA) approved several therapies, and more.

Women with gynecologic cancers may find themselves in a whole new world of improved quality of life by tuning into Disney movies, according to a study.

According to a survey from the American Cancer Society, just more than half of grantees reported that their cancer research or training activities had been put on hold due to the COVID-19 pandemic.

The FDA approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.

The FDA approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell lung cancer with the MET exon 14 skipping mutations, making it the first FDA approval to target these mutations.

In case you missed it, more hem/onc headlines are featured below:

• FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
• Obamacare Led to Decrease in Cancer Mortality, According to Memorial Sloan Kettering Cancer Center Researchers
• Here’s How Primary Cancer Physicians View Their Care Delivery Roles for Survivors
• Scientists Develop First Saliva Test That Detects Throat Cancer in Asymptomatic Patients